Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will be featured in HighRes’ Lightning Talk at the NVIDIA GTC AI ...

So you're spooked by a viral essay. How about, I don't know, looking at the data?

Recursion Pharmaceuticals (RXRX) stock surged after the company significantly beat Street forecasts with its Q4 2025 results.

Guidance extended from year-end 2027 to early 2028, with operating expense reduction targets reiterated and achieved at a greater scale (now 35% year-over-year, 10% below guidance). Strategic focus ...

Recursion Pharmaceuticals shares were 11% higher, at $3.90, after the company reported fourth-quarter revenue that was higher than last year, and a loss that was narrower than last year's.

Shares of Recursion Pharmaceuticals RXRX are surging Wednesday following a robust earnings report released before the bell. Recursion Pharmaceuticals stock is charging ahead with explosive momentum.

Overview: Strong knowledge of data structures and recognizing common patterns makes complex coding questions easier and faster to solve.Thinking out loud during ...

The resulting outcome is that you have A.I. systems that have learned what it means to solve a problem that takes quite a ...

AI startup Anthropic's claim of automating COBOL modernization sent IBM's stock plummeting, wiping billions off its market value. The decades-old language, still powering critical systems, faces a ...

Overview: The global Artificial Intelligence (AI) in drug discovery market is projected to grow at a rate of 25-30% over the ...